

62 - References

References

60 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Samara MT, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. *Cochrane Database Syst Rev* 2018; (5):CD011884.
2. Barnes T, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2020; 34:3-78.
3. Rubio JM, et al. Early non-response to antipsychotic treatment in schizophrenia: a systematic review and meta-analysis of evidence-based management options. *CNS Drugs* 2023; 37:499-512.
4. Ezewuzie N, et al. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. *J Psychopharm* 2006; 20:86-90.
5. Sparshatt A, et al. Quetiapine: dose-response relationship in schizophrenia. *CNS Drugs* 2008; 22:49-68.
6. Honer WG, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. *J Clin Psychiatry* 2012; 73:13-20.
7. Davis JM, et al. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol* 2004; 24:192-208.
8. Leucht S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *Am J Psychiatry* 2020; 177:342-353.
9. Srisurapanont M, et al. A network meta-analysis of the dose-response effects of lurasidone on acute schizophrenia. *Sci Rep* 2021; 11:5571.
10. Kinon BJ, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. *J Clin Psychopharmacol* 2008; 28:392-400.
11. Marder SR, et al. Risperidone in the treatment of schizophrenia. *Am J Psychiatry* 1994; 151:825-835.
12. Van Putten T, et al. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. *Arch Gen Psychiatry* 1990; 47:754-758.
13. Zimbroff DL, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. *Am J Psychiatry* 1997; 154:782-791.
14. Sifakis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. *Mol Psychiatry* 2023; 28:3267-3277.

15. Kinon BJ, et al. Treatment of neuroleptic-resistant schizophrenic relapse. *Psychopharmacol Bull* 1993; 29:309–314.
16. Hermes E, et al. Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. *Psychiatry Res* 2012; 199:1–7.
17. Loebel A, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. *J Clin Psychiatry* 2016; 77:1672–1680.
18. Jukic MM, et al. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. *Lancet Psychiatry* 2019; 6:418–426.
19. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration: a comparison of a population algorithm and three algorithms based on gene variant models. *J Psychopharmacol* 2023; 37:1030–1039.
20. Patel MX, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. *Eur Neuropsychopharmacol* 2014; 24:499–509.
21. Stokes I, et al. Prevalence of treatment resistance and clozapine use in early intervention services. *BJPsych Open* 2020; 6:e107.
22. Paton C, et al. Is clozapine really under-used? Investigating clinical practice in a community psychosis team. *J Psychiatry Behav Sci* 2023; 6:1089.
23. Heres S, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry* 2006; 163:185–194.
24. Obayashi Y, et al. Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole. *Psychopharmacology (Berl)* 2020; 237:167–175.
25. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. *J Clin Psychiatry* 2007; 68 Suppl 6:10–13.
26. Takeuchi H, et al. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. *Schizophr Bull* 2017; 43:862–871.
27. Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006; 163:611–622.
28. Leucht S, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373:31–41.
29. Leucht S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009; 166:152–163.
30. Hong J, et al. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. *BMC Psychiatry* 2012; 12:218.
31. Agid O, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. *Eur Neuropsychopharmacol* 2013; 23:1017–1022.
32. Gannon L, et al. High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. *Ther Adv Psychopharmacol* 2023; 13:20451253231168788.
33. Dong S, et al. A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia. *Eur Arch Psychiatry Clin Neurosci* 2023; 274:917–928.

34. Stroup TS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). *Am J Psychiatry* 2011; 168:947-956.
35. Montastruc F, et al. Association of aripiprazole with the risk for psychiatric hospitalization, self-harm, or suicide. *JAMA Psychiatry* 2019; 76:409-417.

Schizophrenia and related psychoses CHAPTER 1

36. Pae CU, et al. Effectiveness and tolerability of switching to aripiprazole once monthly from antipsychotic polypharmacy and/or other long acting injectable antipsychotics for patients with schizophrenia in routine practice: a retrospective, observation study. *Clin Psychopharmacol Neurosci* 2020; 18:153-158.
37. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 422. 2022 (last accessed February 2025); <https://www.rcpsych.ac.uk/improving-care/ccqi/national-clinical-audits/pomh>.
38. Wagner E, et al. Clozapine combination and augmentation strategies in patients with schizophrenia - - recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRIP) working group. *Schizophr Bull* 2020; 46:1459-1470.
39. Taylor DM, et al. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. *Acta Psychiatr Scand* 2009; 119:419-425.
40. Grover S, et al. Augmentation strategies for clozapine resistance: a systematic review and meta-analysis. *Acta Neuropsychiatr* 2023; 35:65-75.
41. Kapur S, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. *Am J Psychiatry* 2001; 158:311-314.
42. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. *World Psychiatry* 2017; 16:77-89.
43. Gallego JA, et al. Safety and tolerability of antipsychotic polypharmacy. *Expert Opin Drug Saf* 2012; 11:527-542.
44. Barnes T, et al. Antipsychotic polypharmacy in schizophrenia: benefits and risks. *CNS Drugs* 2011; 25:383-399.
45. Taipale H, et al. Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia. *Am J Psychiatry* 2023; 180:377-385.
46. Borlido C, et al. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2016; 77:e14-e20.
47. Hori H, et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. *J Psychiatr Res* 2013; 47:1843-1848.
48. Essock SM, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. *Am J Psychiatry* 2011; 168:702-708.
49. Constantine RJ, et al. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. *Schizophr Res* 2015; 166:194-200.
50. Royal College of Psychiatrists. The Risks and Benefits of High-Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists; 2014.

Revision #1

Created 2026-01-04 20:13:50 UTC by Omar Ayman

Updated 2026-01-04 20:13:50 UTC by Omar Ayman